Pramlintide is used as an adjunct in a patient with type 1 diabetes to reduce postprandial glucose excursions. Pramlintide is a synthetic analog of amylin. Which mechanism best describes its glucose-lowering effect?

• A It directly stimulates insulin secretion from pancreatic beta cells independent of glucose
• B It slows gastric emptying, suppresses glucagon secretion, and promotes satiety via hypothalamic receptors ✓
• C It inhibits hepatic glycogenolysis through AMPK activation
• D It blocks renal glucose reabsorption at SGLT2 transporters

Explanation

Pramlintide is a synthetic amylin analog that acts on area postrema and hypothalamic receptors to slow gastric emptying, suppress postprandial glucagon secretion, and promote satiety. These combined effects reduce postprandial glucose excursions. It is approved only for type 1 and type 2 diabetes already using mealtime insulin, and it carries a boxed warning for severe hypoglycemia risk.

Reference: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 14th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.